Get started
Author

Sophie E. Berends

Observed names: Berends, Sophie, Berends, Sophie E, Berends, Sophie E., Huiskes-Berends, Sophie, S Berends, S E Berends, S. Berends, Sophie Berends, Sophie E Berends
Institution: Lygature
ORCID: 0000-0002-3236-0698
Observed ORCID: 0000-0002-3236-0698
OpenAlex ID: A5010223613
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
2018 · Sophie E. Berends, Anne S. Strik, et al. · Clinical Pharmacokinetics · 141
PDF
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease
2019 · Mark Löwenberg, Severine Vermeire, et al. · Gastroenterology · 131
Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
2020 · Anne S. Strik, Mark Löwenberg, et al. · Scandinavian Journal of Gastroenterology · 121
PDF
Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease
2018 · Sophie E. Berends, Anne S. Strik, et al. · Therapeutic Drug Monitoring · 42
PDF
Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
2019 · Sophie E. Berends, Geert R. A. M. D'Haens, et al. · British Journal of Clinical Pharmacology · 39
PDF
DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
2019 · A Strik, S Berends, et al. · Journal of Crohn s and Colitis · 39
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
2020 · Erwin Dreesen, Sophie Berends, et al. · British Journal of Clinical Pharmacology · 33
PDF
Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
2019 · Sophie E. Berends, Tamara J. van Steeg, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 20
PDF
Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study
2019 · Sophie E. Berends, Anne S. Strik, et al. · Scandinavian Journal of Gastroenterology · 20
PDF
Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients
2021 · C J Hodiamont, N P Juffermans, et al. · Journal of Antimicrobial Chemotherapy · 19
PDF
Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples
2019 · Sophie E. Berends, Karien Bloem, et al. · Therapeutic Drug Monitoring · 18
PDF
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
2022 · Selma Atalay, Sophie E. Berends, et al. · Journal of Dermatological Treatment · 14
PDF
Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
2019 · Anne S Strik, Sophie E Berends, et al. · Expert Review of Clinical Pharmacology · 12
Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?
2024 · Lourens T. Bloem, Hubert G.M. Leufkens, et al. · Drug Discovery Today · 11
DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
2018 · S Berends, M Löwenberg, et al. · Journal of Crohn s and Colitis · 8
Golimumab for moderate to severe ulcerative colitis
2017 · Anne S. Strik, Sophie E. Berends, et al. · Expert Review of Gastroenterology & Hepatology · 8
Population Pharmacokinetics of Infliximab in Children with Juvenile Idiopathic Arthritis
2021 · Amara Nassar-Sheikh Rashid, Dieneke Schonenberg-Meinema, et al. · Therapeutic Drug Monitoring · 4
832 – Dashboard Driven Dosing of Infliximab is Superior to Conventional Treatment in Inflammatory Bowel Disease: the Precision Randomized Controlled Trial
2019 · Anne S. Strik, Sophie E. Berends, et al. · Gastroenterology · 4
DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
2020 · E Dreesen, S Berends, et al. · Journal of Crohn s and Colitis · 3
PDF
P597 Optimising therapeutic drug monitoring of adalimumab with dried blood samples in IBD patients: an interim analysis
2019 · S Berends, K Bloem, et al. · Journal of Crohn s and Colitis · 1
Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab
2018 · Anne S Strik, Erwin Dreesen, et al. · Cochrane Database of Systematic Reviews · 1
Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial
2018 · Sophie E. Berends, Mark Löwenberg, et al. · Gastroenterology · 1
P690 Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational study
2018 · S Berends, A Strik, et al. · Journal of Crohn s and Colitis · 1
Shaping the potential of a Dutch ATMP network: Report of the RSNN SIG Advanced Therapies and FAST workshop on 11 June 2024
2024 · Hoek, Joyce M, Warmerdam, Daniël O, et al. · Utrecht University Repository (Utrecht University)
Pos0070 Population Pharmacokinetics of Infliximab in Children With Juvenile Idiopathic Arthritis
2021 · A. Nassar-Sheikh Rashid, D. Schonenberg-Meinema, et al. · Annals of the Rheumatic Diseases
PDF
Works count: 36
Citation count: 691
H-index: 12
I10-index: 14
Year
Topic
Type